Welcome to our dedicated page for Perrigo news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on Perrigo stock.
Perrigo Company plc reports recurring developments as a pure-play consumer health company focused on over-the-counter self-care products, store-brand private label offerings, and branded health and wellness products primarily in North America and Europe. Company updates cover operating results from continuing operations, category performance, dividends, investor presentations, and portfolio actions under its Three-S plan to stabilize, streamline, and strengthen the business.
News also addresses Perrigo's product-category reporting and brand momentum across Self Care and Specialty Care, including names such as Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®. Recent corporate developments include the completed divestiture of the Dermacosmetics business and the use of portfolio proceeds for balance-sheet debt reduction.
Perrigo Company plc (NYSE; TASE: PRGO) will announce its second quarter financial results on August 5, 2020, with a conference call scheduled for 9:00 a.m. (EDT). Interested investors can access the call via webcast on Perrigo's investor relations website or by phone. A replay will be available from 12:00 p.m. (EDT) on the same day until midnight on August 12, 2020. The company focuses on providing affordable self-care products, enhancing the well-being of consumers, and is dedicated to transparency regarding future financial performance and associated risks.
Perrigo Company plc (NYSE: PRGO) has successfully closed a public offering of $750 million in 3.150% Senior Notes due 2030. The offering aims to collect approximately $737.1 million in net proceeds after expenses. Perrigo plans to utilize these proceeds primarily to redeem existing 3.500% Senior Notes due in 2021 and for other corporate purposes. The offering was managed by BofA Securities, J.P. Morgan, and Wells Fargo Securities.
Perrigo Company plc has finalized an agreement to sell its U.K.-based Rosemont Pharmaceuticals for £156 million, approximately $195 million, to a private equity firm. This deal marks a key step in Perrigo's strategy to transition to a consumer-focused self-care company. In 2019, Rosemont generated net sales of $53 million and contributed $0.12 to adjusted diluted EPS. CEO Murray S. Kessler emphasized the successful divestiture at an attractive tenfold adjusted operating income multiple, demonstrating commitment to shareholder value.
Perrigo Company plc (NYSE; TASE: PRGO) announced on June 17, 2020, a strategic investment in Kazmira LLC to enter the rapidly expanding CBD market. The deal includes a minority equity stake of approximately 20% for $50 million, aimed at producing THC-free CBD through a two-phase partnership. The first phase will enhance Kazmira's facilities to meet high-quality standards, while the second phase will launch CBD products in global markets. This collaboration aligns with Perrigo's vision to provide trusted self-care products and is expected to drive long-term growth for shareholders.
Perrigo Company plc announced a public offering of $750 million in 3.150% Senior Notes due 2030, priced at 99.170% of the principal amount. These notes will be fully guaranteed by Perrigo and are intended to fund the redemption of existing 3.500% Senior Notes due in 2021. The offering is expected to close on June 19, 2020, subject to customary conditions. This move aims to optimize financial costs by replacing higher interest debt with lower interest notes, thereby enhancing Perrigo's financial flexibility.
Perrigo Company plc (NYSE: PRGO) announced a public offering of senior notes by its wholly-owned finance subsidiary, Perrigo Finance Unlimited Company. The offering will fund the redemption of existing senior notes due in 2021, with any remaining proceeds allocated for general corporate purposes. The offering is dependent on market conditions, with BofA Securities, J.P. Morgan, and Wells Fargo Securities serving as joint book-running managers. The company emphasizes that this press release does not constitute an offer to sell securities.